Utidelone Capsule Plus Capecitabine (CAP) for Metastatic Breast Cancer
This study aims to investigate the efficacy and safety of utidelone capsule plus Capecitabine in the treatment of advanced breast cancer , and thus provides a new systemic treatment strategy for those patients.

This study was a single-arm, phase II study of patients with recurrent or metastatic HER2-negative breast cancer who had previously received chemotherapy regimens containing taxanes and/or anthracyclines were treated with a combination of utidelone capsules and capecitabine. The main objective was to explore the efficacy and safety of the combined regimen.
Breast Cancer Recurrent
DRUG: Utidelone Capsule Plus Capecitabine
Objective Response Rate （ORR）, ORR is defined as the percentage of participants in the analysis population who have CR or PR per RECIST 1.1., 18 months
Progression-Free Survival（PFS）, time from the first dose to disease progression or any-cause death, 18 months|Disease Control Rate （DCR）, DCR is defined as the percentage of participants in the analysis population who have CR or PR or SD per RECIST 1.1., 18 months|Duration of response (DoR), DOR is defined as the interval from response initiation (when either CR or PR is first determined) to progression or death, whichever occurs first., 18 months|Overall survival (OS), time from the first dose of study drug to any-cause death, 18 months|Treatment-related Adverse Event-TRAE, Number of participants with treatment-related adverse events as assessed by CTCAE v5.0, Until 28 days after the last dose of treatment
Patients with recurrent or metastatic HER2 negative breast cancer who have previously received chemotherapy containing taxanes and/or anthracyclines will receive combined treatment with utidelone capsule and capecitabine. Utidelone Capsule: 60mg/m2/d, once daily, oral on an empty stomach, continuously administered for 1-5 days; Capecitabine tablets: 1000mg/m2, twice a day (daily dose 2000mg/m2), once in the morning and once in the evening, taken orally within 30 minutes after meals, and continuously administered for 14 days from day 1 to day 14. Every 21 days is a cycle until disease progression, intolerable adverse events occur, subjects voluntarily withdraw, or the researcher determines that medication must be terminated.